Summary
Antigens in a particulate conformation were shown to be highly immunogenic in mammals. For this reason, the particle forming capacity of derivatives of the HIV-1 group specific core antigen p 55gag was assayed and compared dependent on various expression systems: recombinant bacteria, vaccinia-and baculoviruses were established encoding the entire core protein p 55 either in its authentic sequence or lacking the myristylation consensus signal. Moreover, p 55gag was expressed in combination with the protease (p 55-PR) or with the entire polymerase (p 55-pol), respectively. Budding of 100–160 nm p 55 core particles, resembling immature HIV-virions, was observed in the eucaryotic expression systems only. In comparison to the vaccinia virus driven expression of p 55 in mammalian cells, considerably higher yields of particulate core antigen were obtained by infection ofSpodoptera frugiperda (Sf9) insect cells with the recombinantAutographa californica nuclear polyhedrosis (AcMNPV) baculovirus. Mutation of the NH2-terminal myristylation signal sequence prevented budding of the immature core particles. Expression of the HIV p 55-PR gene construct by recombinant baculovirus resulted in complete processing of the p 55gag precursor molecule in this system. The introduction of an artificial frameshift near the natural frameshift site resulted in constitutive expression of the viral protease and complete processing of p 55, both inEscherichia coli and in vaccinia virus infected cells. Interestingly, significant processing of p 55 resembling that of HIV infected H 9 cells could also be achieved in the vaccinia system by fusing the entirepol gene to thegag gene. Moreover, processing was not found to be dependent on amino-terminal myristylation of thegag procursor molecule, which is in contrast to observations with type C and type D retrovirus. However, complete processing of p 55 into p 24, p 17, p 9 and p 6 abolished particle formation. Purified immature HIV-virus like particles were highly immunogenic in rabbits, leading to a strong humoral immune response after immunization. Empty immature p 55gag particles represent a noninfectious and attractive candidate for a basic vaccine component.
Article PDF
Similar content being viewed by others
References
Beesley KM, Francis MJ, Clarke BE, Beesley IE, Dopping-Heppenstal PJ, Clare JJ, Brown F, Romanos MA (1990) Expression in yeast of aminoterminal peptide fusions to hepatitis B core protein antigen and their immunological properties. Biotechnology 8: 644–649
Debouck C, Gorniak JG, Stricker JE, Meek TD, Metcalf BW, Rosenberg M (1987) Human immunodeficiency virus protease expressed inEscherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 84: 8903–8906
Delchambre M, Gheysen D, Thines D, Thiriart C, Jacobs E, Verdin E, Horth M, Burny A, Bex F (1989) The gag precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 8: 2653–2660
Flexner C, Broyles SS, Earl P, Chakrabarti S, Moss B (1988) Characterization of human immunodeficiency virusgag/pol gene products expressed by recombinant vaccinia viruses. Virology 166: 339–349
Gelderblom HR, Ozel M, Pauli G (1989) Morphogenesis and morphology of HIV. Structure-function relations. Arch Virol 106: 1–13
Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, Thines D, de Wilde M (1989) Assembly and release of HIV-1 precursor Pr 55 gag virus like particles from recombinant baculovirus infected cells. Cell 59: 103–112
Gilmour JE, Senior JM, Burns NR (1989) A novel method for the purification of HIV-1 p 24 protein from hybrid Ty virus-like particles (TY-VPL's). J Aqu Immunodef Synd 3: 717–723
Göttlinger HE, Sodroski JG, Haseltine WA (1989) Role of the capsid precursor processing and miristylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86: 5781–5785
Gowda SD, Stein BS, Engelman EG (1989) Identification of protein intermediates in the processing of the p 55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus. J Biol Chem 264: 8459–8462
Gregersen JE, Wege H, Preiss L, Jenatsch KD (1988) Detection of human immunodeficiency virus and other retroviruses in cell culture supernatants by a reverse transcriptase microassay. J Virol Methods 19: 161–168
Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL (1990) Human immunodeficiency virus-like, nonreplicating particles assemble in a recombinant vaccinia virus expression system. J Virol 64: 2653–2659
Haynes JR, Cao SX, Rovinski B, Sia C, James O, Dekaban GA, Klein MH (1991) Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Human Retroviruses 7: 17–27
Henderson LE, Krutzsch HC, Oroszlan S (1983) Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-transcriptional protein modification. Proc Natl Acad Sci USA 80: 339–343
Jacks T, Madhani HD, Masiarz FR, Varmus HE (1988) Signals for ribosomal frame-shifting in Rous sarcoma virus gag-pol region. Cell 55: 447–458
Kaplan LM, Mardon G, Bishop JM, Varmus HE (1988) The first seven amino acids encoded by v-src oncogene act as a myristylation signal; lysine 7 is a critical determinant. Mol Cell Biol 8: 2435–2441
Katsumoto L, Hattori N, Kurimura T (1987) Maturation of human immunodeficiency virus, strain LAV, in vitro. Intervirology 27: 148–153
Kingsman SM, Kingsman AJ (1989) Host vector systems. Philos Trans R Soc Lond [Biol] 324: 477–485
Kingsman SM, Adams SE, Kingsman AJ (1989) The yeast retrotransposon Ty: molecular genetics and exploitation. Biotechnology 13: 145–163
Kramer RA, Schaber MD, Skalka AD, Ganguly K, Wong Staal F, Reddy EP (1986) HTLV-III gag protein is processed in yeast by the virus pol protease. Science 231: 1580–1584
Kräuslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E (1988) Processing of in vitro synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated inEscherichia coli. J Virol 62: 4393–4397
Laemmli U (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T 4. Nature 227: 680–685
Lever A, Göttlinger H, Haseltine W, Sodroski J (1989) Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63: 4085–4087
Lillehoj EP, Salazar FH, Mervis RJ, Raum MG, Chan HW, Ahmad N, Venkatesan S (1988) Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol 62: 3053–3058
Mackett MG, Smith L, Moss B (1984) General method for production and selection of infectious vaccinia virus recombinants expressing recombinant foreign genes. J Virol 49: 857–864
Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, Venkatesan S (1988) The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications and evidence for alternative gag precursors. J Virol 62: 3993–4002
Michel ML, Mancini M, Riviere Y, Dormont D, Tiollais P (1990) T- and B-lymphozyte responses to human immunodeficiency virus (HIV) type 1 in macaques with hybrid HIV/hepatitis B surface antigen particles. J Virol 64: 2452–2455
Mills KH, Kitchin PA, Mahon BP, Barnard AL, Adams SE, Kingsman SM (1990) HIV p 24-specific helper T-cell clones from immunized primates recognize highly conserved regions of HIV-1. J Immunol 144: 1677–1683
Nixon DF, Townsand AR, Elvin JG, Rizza CR, Gallway J, McMichael AJ (1988) HIV-1 gag specific cytotoxic T-lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336: 484–487
Overton HA, Fuji Y, Price IR, Jones IM (1989) The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology 170: 107–116
Papsidero LD, Sheu M, Ruscetti FW (1989) Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p 17 core protein: characterization and epitope mapping. J Virol 63: 267–272
Ratner L, Haseltine W, Patarca R (1985) Complete nucleotide sequence of the AIDS virus, HTLV III. Nature 313: 227–284
Rein A, McClure MR, Rice NR, Luftig RB, Schultz AM (1986) Myristylation site in Pr 65 gag is essential for virus particle foramtion by Moloney murine leucemia virus. Proc Natl Acad Sci USA 83: 7246–7250
Rhee SS, Hunter E (1987) Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol 61: 1045–1053
Sambrook I, Fritsch EF, Maniatis T (1989) Molecular cloning; a laboratory manual. Cold Spring Harbor Laboratory, New York
Schultz AM, Oroszlan S (1983) In vivo modification of retroviral gag gene-encoded polyproteins bymyristic acid. J Virol 46: 355–361
Shioda T, Shibuta H (1990) Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175: 139–148
Smith AJ, Cho MI, Hammarskjold ML, Rekosh D (1990) Human immunodeficiency virus type 1 Pr 55 gag and Pr 150 gagpol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus like particles. J Virol 64: 2743–2750
Smith GE, Ericson BL, Moschera J, Lahm HW, Chizzonite R, Summers MD (1985) Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. Proc Natl Acad Sci USA 82: 8404–8408
v Brunn A (1989) Das Oberflächenantigen des Hepatitis B Virus als Trägersystem von Epitopen eines merozoiten Oberflächenmoleküls des Malariaerregers Plasmodium Falciparum — eine neue Möglichkeit der Impfstoffentwicklung? PhD Thesis, University of Munich, Munich, Federal Republic of Germany
Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 347–350
Veronese FD, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG (1988) Biochemical and immunological analysis of human immunodeficiency virusgag gene products p 17 and p24. J Virol 62: 795–801
Walker BD, Chakrabarti S, Moss B (1987) HIV specific cytotoxic T-lymphocytes in seropositive individuals. Nature 328: 345–348
Wilcox C, Hu JS, Olson EN (1987) Acylation of proteins with myristic acid occurs cotranslationally. Science 238: 1275–1278
Wolf H, Modrow S, Soutschek E, Motz M, Grunow R, Döbl H, v Baehr R (1990) Herstellung, Kartierung und biologische Charakterisierung von monoklonalen Antikörpern gegen das core protein (p 24) des humanen Immundefizienz-Virus. AIFO 1: 24–29
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, R., Fließbach, H., Wanner, G. et al. Studies on processing, particle formation, and immunogenicity of the HIV-1gag gene product: a possible component of a HIV vaccine. Archives of Virology 127, 117–137 (1992). https://doi.org/10.1007/BF01309579
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01309579